Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-22-217405
Filing Date
2022-08-10
Accepted
2022-08-10 16:32:17
Documents
47
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q d383174d10q.htm   iXBRL 10-Q 648019
2 EX-31.1 d383174dex311.htm EX-31.1 7595
3 EX-31.2 d383174dex312.htm EX-31.2 7533
4 EX-32.1 d383174dex321.htm EX-32.1 3964
5 EX-32.2 d383174dex322.htm EX-32.2 3933
  Complete submission text file 0001193125-22-217405.txt   3471245

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA bios-20220630.xsd EX-101.SCH 35801
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE bios-20220630_cal.xml EX-101.CAL 14919
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE bios-20220630_def.xml EX-101.DEF 189975
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE bios-20220630_lab.xml EX-101.LAB 238125
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bios-20220630_pre.xml EX-101.PRE 224027
41 EXTRACTED XBRL INSTANCE DOCUMENT d383174d10q_htm.xml XML 451611
Mailing Address 260 MADISON AVENUE, SUITE 800 NEW YORK NY 10016
Business Address 260 MADISON AVENUE, SUITE 800 NEW YORK NY 10016 2122874092
BioPlus Acquisition Corp. (Filer) CIK: 0001856653 (see all company filings)

EIN.: 981583272 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41116 | Film No.: 221152282
SIC: 6770 Blank Checks